Novartis’ Cosentyx received CFDA (Chainese) approval to treat adults with plaque psoriasis
Posted on03 Apr 2019
Comments0
Novartis, a global leader in immuno-dermatology and rheumatology, announced that the China Health Authority NMPA approved Cosentyx (secukinumab), the first-in-class interleukin-17A (IL-17A)... Read More
Janssen enters license agreement with chinese company legend biotech to develop CAR-T anti-cancer therapy
Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson has announced that it has entered into a worldwide collaboration and license... Read More
Overview of China Pharmaceutical Market
The China pharmaceutical market is the second largest in the world after the United States, and in 2014 was worth 109.3 billion... Read More